-+ 0.00%
-+ 0.00%
-+ 0.00%
CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drug
Share
Listen to the news
CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drug
  • CSPC received China NMPA clearance in August 2026 to start clinical trials of SYH2092 for weight management in overweight adults.
  • A first Phase 1 site in China has initiated dosing, testing single-dose safety, tolerability, pharmacokinetics, pharmacodynamics in healthy volunteers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12309181), on August 31, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending